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esponsibility of Xi’Abstract CDRI compound no. 99/411 is a potent 1,2,4-trioxane antimalarial candidate drug under
development at our Institute. An HPLC method for determination of CDRI 99/411 with its starting
material and intermediates has been developed and validated for in process quality control and stability
studies. The analytical performance parameters such as linearity, precision, accuracy, speciﬁcity, limit of
detection (LOD) and lower limit of quantiﬁcation (LLOQ) were determined according to International
Conference on Harmonization ICH Q2(R1) guidelines. HPLC separation was achieved on a RP-select B
Lichrospheres column (250 mm 4 mm, 5 μm, Merck) using water containing 0.1% glacial acetic acid
and acetonitrile as the mobile phase in a gradient elution. The eluents were monitored by a photo diode
array detector at 245 and 275 nm. Based on signal to noise ratio of 3 and 10 the LOD of CDRI 99/411 was
0.55 mg/mL, while the LLOQ was 1.05 mg/mL. The calibration curves were linear in the range of 1.05–
68 mg/mL. Precision of the method was determined by inter- and intra-assay variations within the
acceptable range.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Elsev
3
s Division, CSIR-Central Drug
Road, Lucknow 226001, India.
938.
.K. Dwivedi).
an Jiaotong University.1. Introduction
Malaria is still one of the major infectious diseases caused by a
protozoa Plasmodium falciparum, with billions of people at risk
for this deadly disease especially in underdeveloped countries
[1–4]. The developing world urgently needs new, safe, and
effective antimalarial drugs as the failure of the contemporary
drugs due to the increasing resistance of the malaria parasite has
further complicated the problem of treating malaria [5]. Semisyn-
thetic derivatives of artemisinin are effective against both the
chloroquine-sensitive and chloroquine-resistant malaria, hence
used for the treatment of malaria caused by multidrug resistant
P. falciparum [6]. CDRI 99/411 (Fig. 1) is a potent orally activeier B.V. All rights reserved.
K. Khandelwal et al.3361,2,4-trioxane antimalarial candidate compound for the treatment
of malaria [7–8]. 1,2,4-Trioxane ring system in artemisinin is
essential for the antimalarial activity due to the presence of
peroxide group [9]. A synthetic analog of this is a better
replacement for management of falciparum malaria. Patent for
CDRI 99/411 is granted as it has shown a good proﬁle for
development as a drug and hence has been taken up for further
development at our Institute [10]. Synthesis of CDRI 99/411 is
shown in Fig. 2. In this reaction 1-(4-cyclohexylphenyl) ethanone
(1) is converted to ethyl 3-(4-cyclohexylphenyl)-but-2-enoate (2)
and the resulting ester is converted to 3-(4-cyclohexyl- phenyl)-
but-2-en-1-ol (3), which ﬁnally results into CDRI 99/411 after
peroxidation with 2-admantanone. In a multistep synthesis, the
starting material and the intermediates may form the process
impurities; thus there is a need for an analytical tool for
identiﬁcation and quantiﬁcation of CDRI 99/411[11]. Liquid
chromatography is usually an analytical method of choice for
pharmaceutical quality control [12], so the present study was
undertaken to develop and validate an HPLC method for CDRI 99/
411 having good separation of starting material, intermediates for
process quality control and degradation products in stress stability
studies.2. Experimental
2.1. Reagents and standards
Standard CDRI 99/411, starting material (1) and intermediates (2, 3)
were supplied by the Medicinal and Process Chemistry Division of
our Institute. HPLC grade acetonitrile was obtained from Spectro-
chem Pvt. Ltd. (Mumbai, India) and glacial acetic acid (analytical
grade) from E. Merck (India) Ltd. (Mumbai, India). Milli-Q pure
water was obtained from a Millipore Elix water puriﬁcation systemFig. 1 Chemical structures of CDRI 99/411.
Fig. 2 Schematic representationpurchased from Millipore India Pvt. Ltd. (New Delhi, India). Other
reagents used were of analytical grade.
2.2. Apparatus and chromatographic conditions
Waters HPLC (Milford, MA, USA) system was equipped with a
binary gradient pump (model 515, Waters), an auto sampler
injector (Model 2707, Waters) and a diode array detector (Model
2998, Waters). The sample and standard solution were analyzed by
HPLC after injecting 20 mL. The following gradient was used with
(A) water containing 0.1% glacial acetic acid and (B) acetonitrile:
0 min, 30:70 (A:B); 5 min, 10:90; 15 min, 10:90; 17 min, 30:70;
and 20 min, 30:70. HPLC separation was achieved on a RP-select
B Lichrosphers column (250 4 mm, 5 μm, Merck, Germany).
Column efﬂuent was monitored at 245 and 275 nm. The solutions
were ﬁltered and degassed before use. Chromatography was
performed at 30 1C at a ﬂow rate of 1.0 mL/min. Data were
acquired and processed using Waters HPLC interface and soft-
ware, Empower 2.
2.3. Preparation of stock and working standard solutions
Primary stock solutions of compounds 1, 2, 3 and CDRI 99/411 were
prepared by dissolving the respective compounds in acetonitrile to
achieve concentrations of 2.06, 1.92, 1.42 and 1.36 mg/mL respec-
tively. These solutions were further diluted by transferring 1 mL each
of the above stocks into 10 mL volumetric ﬂask and making up to the
volume with acetonitrile. Finally, solutions were prepared by diluting
the diluted solution with acetonitrile to achieve different dilutions
required for calibration of these compounds.
2.4. Preparation of sample solution
The stock solutions for samples of bulk candidate drug prepared
for preclinical studies and samples from the stability chambers
were prepared by dissolving these samples in acetonitrile. These
samples were analyzed after dilution of stock with acetonitrile.
2.5. Method validation
2.5.1. Speciﬁcity and selectivity
The chromatographic interferences were assessed by comparing
chromatograms of blank acetonitrile with those of samples spiked
with compounds 1, 2, 3 and CDRI 99/411 in acetonitrile.of synthesis of CDRI 99/411.
Fig. 3 HPLC chromatogram of mixture of compounds 1, 2, 3 and CDRI 99/411.
Table 1 Regression data, limit of detection (LOD) and lower limit of quantiﬁcation (LLOQ) for compounds CDRI 99/411, 1, 2 and 3.
Compounds LOD (μg/mL) LLOQ (μg/mL) Linear range (μg/mL) Regression equation r2
1-(4-Cyclohexylphenyl) ethanone (1) 0.4 0.80 0.8–25.7 y¼74,344x+2464 0.999
Ethyl 3-(4-cyclohexylphenyl)-but-2-enoate (2) 0.38 0.75 0.75–24.0 y¼22,148x2266 0.999
3-(4-Cyclohexyl- phenyl)-but-2-en-1-ol (3) 0.28 1.10 1.1–35.5 y¼72,196x−1041 0.999
CDRI 99/411 0.52 1.05 1.05–68.0 y¼37,764x−1694 0.999
Table 2 Intra- and inter-day assay variation of compounds 1, 2, 3 and CDRI 99/411.
Compounds Concentration taken Intra-day assay variationa Inter-day assay variationb
Conc. found
(mean7SD; mg/mL)
RSD DFA (%) Conc. found
(mean7SD; mg/mL)
RSD DFA (%)
Compound-1 25.70 25.7270.07 0.26 0.07 25.7670.02 0.06 0.22
6.40 6.3970.03 0.41 −0.68 6.3770.03 0.54 −0.91
0.80 0.7770.02 2.98 −3.21 0.7470.03 4.20 −6.18
Compound-2 24.00 24.0870.23 0.95 0.34 24.0870.23 0.95 0.34
6.00 6.0270.08 1.31 0.30 6.0970.04 0.68 1.43
0.75 0.7970.01 0.78 4.91 0.7970.01 0.66 5.44
Compound-3 35.50 35.7270.30 0.83 0.63 35.8070.24 0.67 0.84
8.80 8.9370.05 0.55 1.43 8.9470.06 0.71 1.63
1.10 1.1370.13 0.94 2.47 1.1570.01 1.01 4.82
Final product
(CDRI 99/411)
34.00 34.0770.07 0.21 0.20 34.0870.06 0.18 0.22
8.50 8.5870.07 0.85 0.98 8.5870.13 1.55 0.95
1.05 1.0970.02 1.90 3.60 1.1270.03 2.93 6.60
aDetermined with three replicates at each concentration.
bDetermined with nine replicates (day 1, n¼3; day 2, n¼3; day 3, n¼3) at each concentration.
An HPLC method for CDRI 99/411 3372.5.2. Linearity of calibration curves
The linearity of the method was established by constructing calibra-
tion curves over a concentration range of 0.8–25.7, 0.75–24.0,
1.1–35.5 and 1.05–68.0 mg/mL for compounds 1, 2, 3 and CDRI
99/411, respectively. Plots of peak area (response) against analyte
concentration were used. The slope, intercept and the correlation
coefﬁcient of each calibration curve were determined using linear
regression analysis.2.5.3. Accuracy and precision
In order to assess the intra- and inter-day precision and accuracy of
the assay, quality control (QC) samples at low, medium and highconcentrations were prepared as described above. The intra-day
precision of the assay was assessed by calculating the relative standard
deviation (RSD) for the analysis of QC samples in three replicates and
inter-day precision was determined by the analysis of three replicates
QC samples on three consecutive days. The accuracy was calculated
on the basis of the difference in the mean calculated concentration and
concentration taken (% deviation from actual concentration, % DFA).2.6. Stability studies
Forced degradation studies were performed to evaluate the stability
indicating properties and speciﬁcity of the method [13]. All solutions
K. Khandelwal et al.338used for stress studies were prepared with acetonitrile at an initial
concentration of 1 mg/mL of CDRI 99/411 and heated at 80 1C and
then diluted with acetonitrile to give a ﬁnal concentration of 50 mg/mL.
The acidic degradation of CDRI 99/411 was studied in
hydrochloric acid (0.1 M) at 80 1C for 8 h and alkaline degradation
was studied in sodium hydroxide (0.1 M) at 80 1C for 1 h and the
stressed samples were instantly cooled and diluted with acetoni-
trile. Oxidation was conducted by reﬂuxing with 3% H2O2 for 1 h
at 80 1C and then diluted with acetonitrile.Fig. 4 Chromatogram of standard CDRI 99/411(A) and representative ch
(D) degradations.3. Results and discussion
3.1. Chromatography
The purpose of this study was to develop an HPLC method for in
process quality control and for stability studies. During the method
development, priority was given for the complete separation of the
compound of interest CDRI 99/411 from other starting material
and intermediates involved in the process of synthesis of the ﬁnalromatograms of CDRI 99/411 on acidic (B), alkaline (C) and oxidative
Table 3 Forced degradation studies of CDRI 99/411.
Stress conditions Drug
recovereda
(%)
Drug
decomposeda
(%)
Standard drug 100.00 0.00
Acidic hydrolysis 60.17 39.83
Alkaline hydrolysis 62.95 37.05
Oxidative degradation 83.50 16.50
aDetermined with three replicates.
An HPLC method for CDRI 99/411 339product. Optimum chromatographic conditions were obtained after
running various combinations of acetonitrile and water with glacial
acetic acid as the mobile phase with C18 (Lichrocarts column;
250 4 mm, 5 μm, Merck), Cyno (Lichrocarts column;
250 4 mm, 5 μm, Merck) and RP-select B (Lichrosphers
column; 250 4 mm, 5 μm, Merck) columns. C18 and Cyno
columns resulted in peak with tailing and higher ﬂow rate was
required. Finally RP-select B Lichrosphers column was used for
the study as it gave sharp peak for compounds CDRI 99/411, 1, 2
and 3. Gradient elution was preferred over the isocratic method as
separation of compounds 1 and 2 was not proper.3.2. Selectivity and speciﬁcity
The retention times of compounds 1, 2, 3 and CDRI 99/411 were
5.4, 5.8, 8.35 and 11.93 min, respectively. On a RP-select B
Lichrosphers column, compounds were separated on the basis of
their polarity. Compound-3 contains hydroxyl group which makes
it more polar thus eluting ﬁrst i.e., with less retention time, next
comes compound-1 which has a ketonic group followed by
compound-2 which is a conjugated ester, less polar than ketone,
and hence elutes after compound-1. CDRI 99/411 has a substituted
peroxide bond and an ether linkage; consequently it is least polar
and therefore it has the longest retention time. It should be recalled
that compound 1 is the starting material, whereas compounds 2
and 3 are intermediates in the synthesis of ﬁnal compound CDRI
99/411. None of the above compounds interfered with the peak
corresponding to CDRI 99/411 or with each other (Fig. 3).3.3. Linearity, limits of detection and quantiﬁcation
The calibration curves (n¼3) showed a linear relationship between
peak area and concentration over the ranges of 0.8–25.7, 0.75–
24.0, 1.1–35.5 and 1.05–68.0 mg/mL for compounds 1, 2, 3 and
CDRI 99/411, respectively. The correlation coefﬁcient (r2) of the
calibration curves for all the analytes was found to be more than
0.999. The limits of detection (LOD) and quantiﬁcation (LOQ)
were measured according to the ICH guidelines. The LOD and
LLOQ of the analytes were determined based on a signal to noise
ratio of 3 and 10 respectively (Table 1).3.4. Accuracy and precision
Accuracy and precision data for intra- and inter-day assay are
given in Table 2. The assay values on both occasions (intra- and
inter-day) were found to be within the acceptable limits [14–16].3.5. Stability studies
Chromatograms obtained from the assay of stressed samples are
shown in Fig. 4(A)–(D). CDRI 99/411 shows signiﬁcant degrada-
tion in alkaline and acidic hydrolysis and oxidative stress condi-
tions (Table 3).4. Conclusions
The developed and validated HPLC method is reproducible and
can be routinely used for quality control of CDRI 99/411 in bulk
manufacture, with ongoing stability studies for drug development
process. It provides base line separation of the compound with
all the starting materials, intermediates and product of interest.
Several bulk samples of compound 99-411 from the Medicinal and
Process Chemistry Division and bulk preparation, required for
pharmacological and toxicological studies, were analyzed by the
reported method.
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